Janux Therapeutics, Inc. (JANX) Tops Q1 EPS by 4c

Janux Therapeutics, Inc. (NASDAQ: JANX) reported Q1 EPS of ($0.30), $0.04 better than the analyst estimate of ($0.34). Revenue for the quarter came in at $1.25 million versus the consensus estimate of $658.33 thousand.

For earnings history and earnings-related data on Janux Therapeutics, Inc. (JANX) click here.

You May Also Be Interested In

• Blue Owl leads $2.4 billion debt deal for Iren data center
• NewtekOne cuts EPS guidance, shifts focus to net interest income
• Marvell (MRVL) Stock: Risk/Reward Skewed to the Upside Near-Term Following Selloff, Says Analyst